Over the past several decades, extraordinary breakthroughs in cancer research and treatment have transformed patient outcomes, offering renewed hope to millions of families. The proof is in the numbers. In the mid-1970s, the five-year relative survival rate across all cancers stood at just 49%. Today, that rate has grown to 70%, reflecting decades of progress in cancer research and treatment.
Behind many of these advancements are years of scientific discovery, private investment, and an intellectual property (IP) system that helps turn promising research into lifesaving treatments. By protecting discoveries and providing a pathway for researchers to partner with private companies, strong IP rights are vital to bringing new medicines, immunotherapies, and targeted therapies to patients. As we reflect on National Intellectual Property Month, recognized each October, it is worth examining how these protections have helped transform cancer care and why preserving them is critical to future breakthroughs.
Developing a new drug can take up to 15 years and requires extensive research, rigorous clinical trials, and significant financial investment before it ever reaches patients. For cancer treatments specifically, the path from discovery to approval is often met with setbacks and failed trials, with no guarantee of success. Strong IP protections help create the certainty and predictability needed to encourage scientific collaboration, support continued innovation, and give investors confidence they will be able to get a return on their investment.
The Bayh-Dole Act is a prime example of how IP protections help support medical innovations. Before its passage in 1980, inventions resulting from federally funded research remained under government ownership, making it unattractive for universities and researchers to seek private partners willing to invest in research and development. The Bayh-Dole Act changed that by allowing universities, nonprofit research institutions, and small businesses to retain patent rights to inventions developed from federally funded research. This created a framework for researchers to license discoveries to private companies with the resources and expertise to transform early-stage scientific findings into innovative therapies for patients.
This framework has been especially important in cancer research. By allowing institutions to protect and license their discoveries, Bayh-Dole helps bridge the gap between publicly funded research and the private investment needed to conduct clinical trials, navigate regulatory approval, and bring new cancer therapies to market.
The value of these investments, supported by strong patent protections through laws like Bayh-Dole, is already evident in the remarkable progress transforming cancer care. Advancements in immunotherapy, a treatment that harnesses the body’s immune system to recognize and attack cancer cells, have revolutionized how doctors treat certain cancers. One example is ipilimumab, an immunotherapy developed from early scientific discoveries, then patented and licensed for further commercial development, that brought another lifesaving cancer treatment to patients.
In one landmark clinical trial, 52% of patients with advanced melanoma who received a newer combination of immunotherapies survived at least five years, compared to just 26% who received a single earlier-generation immunotherapy. Nationally, five-year survival for metastatic melanoma has more than doubled since the mid-1990s from 16% to 35%, demonstrating the value of medical innovation that strong IP protections help support.
This progress is encouraging, and a powerful testament to America’s growing innovation ecosystem. However, proposals to weaken IP protections or impose government price control on innovative medicines threaten to undermine this progress. For example, calls to use the federal government’s march-in authority under the Bayh-Dole Act to lower drug prices would undermine the investment incentives that drive cancer research and encourage the commercialization of federally funded discoveries. Similarly, broader government-imposed drug price controls, such as Most-Favored-Nation policies and the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, will chill the investment incentives that strong IP protections provide for cancer research.
National Intellectual Property Month may have come to a close, but we should continue to celebrate the remarkable progress made in the fight against cancer, thanks in large part to the researchers who took big risks and an IP system that made those risks worth taking. The next breakthrough in cancer treatment may already be taking shape in a laboratory today, but turning that discovery into a groundbreaking treatment requires a continued commitment to innovation. Protecting IP rights today means delivering the next generation of lifesaving treatments to tomorrow’s patients.
Gerard Scimeca is an attorney and serves as chairman and co-founder of CASE, Consumer Action for a Strong Economy, a free-market consumer advocacy organization.

The American people sent a clear message this election: Congress must put affordability front and center, and that…

After the January 2025 midair collision near Washington National Airport (DCA), the NTSB cited many probable causes. But…

All year, moderate women told me they weren’t sure their ballots would be counted fairly. On November 3,…
On the record or off. Lawmakers, staffers, lobbyists, journalists — if it belongs on Capitol Hill, we want to hear it.
Thanks for reaching out. We review every pitch and will follow up if we want to pursue the story.